
Engage Bio: Pioneering mRNA treatments to target and eliminate cancer.
Engage Bio, founded by experts in immunotherapy and mRNA therapeutics, is committed to developing mRNA immunotherapies to combat cancer. The company focuses on transforming cancer cells into factories for therapeutic proteins, enabling localized treatment that targets tumors while sparing healthy tissues. Engage Bio's innovative approach aims to provide effective cancer treatment with minimal side effects, positioning it at the forefront of oncology therapeutics.
Notable figures affiliated with Engage Bio include its founders, who have a proven track record with four drugs already in clinical trials. The company has attracted significant interest from investors due to its pioneering technology and potential for high impact in cancer treatment. Engage Bio's achievements in advancing mRNA therapies underscore its potential to revolutionize cancer care, making a significant impact on patient outcomes and the broader medical community.

Sensible Biotechnologies
sensible.bio

Asher Bio
asherbio.com

Rnaimmune
rnaimmune.com

Cisterna Biologics
cisternabx.com

Guardian Bio
guardian-bio.com

Kernal Biologics
kernalbio.com

Cell BioEngines
cellbioengines.com

ParcelBio
parcelbio.com

Cartography Biosciences
cartography.bio

Eugit Therapeutics

Excepgen
excepgen.com

Manhattan BioSolutions

Endpoint Health

ManaT Bio
clasptx.com

Serinus Biosciences
serinus.bio
Companies similar to Engage Bio include Sensible Biotechnologies, Asher Bio, Rnaimmune and Cisterna Biologics.
Engage Bio was founded in 2021.
Engage Bio's headquarters is located in San Carlos, CA, US.
Engage Bio's most recent funding round was for $3.9M (USD) in May 2022.
As of May 1, 2022, Engage Bio has raised a total of $3.9M (USD).